SMARCB1 and rhabdoid tumor: In order to investigate further the effect of FGFR inhibition in rhabdoid tumors, we utilized a murine SNF5 -deficient primary tumor, which was derived from a SNF5-heterozygous background upon spontaneous loss of heterozygosity (LOH) [29], [30], thus closely recapitulating MRT formation in humans.